Shares of Lupin Ltd. gained around 1% on Thursday, April 24, following the announcement of a major product launch in the US market. The pharmaceutical company is set to launch gTolvaptan, the generic version of Otsuka’s Jynarque, as the latter’s exclusivity ends. Lupin will enjoy a 180-day sole generic exclusivity, which could potentially extend further, …